<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e> is an <z:e sem="disease" ids="C0004364" disease_type="Disease or Syndrome" abbrv="">autoimmune disorder</z:e>, defined as the association of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> with manifestations of venous or <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> or pregnancy loss </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">Primary antiphospholipid syndrome</z:e> means that the patients have the same clinical symptoms and laboratory findings but they are not suffering from <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> or a closely related <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0409983" disease_type="Disease or Syndrome" abbrv="">Secondary antiphospholipid syndrome</z:e> occurs in association with autoimmune or other diseases </plain></SENT>
<SENT sid="3" pm="."><plain>AIM, METHODS, RESULTS: 31 pregnancies of 10 women are detailed </plain></SENT>
<SENT sid="4" pm="."><plain>22 pregnancies were without thromboembolic prophylaxis and only 2 pregnancies were successful (9.1%) </plain></SENT>
<SENT sid="5" pm="."><plain>Out of the 9 pregnancies with high dose low-molecular-weight <z:chebi fb="5" ids="28304">heparin</z:chebi> and low dose aspirin thromboprophylaxis throughout pregnancy 8 were successful (88.8%) </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> the newborns were healthy </plain></SENT>
<SENT sid="7" pm="."><plain>In spite of the long-term low-molecular-weight <z:chebi fb="5" ids="28304">heparin</z:chebi> therapy side effects (<z:hpo ids='HP_0000939'>osteoporosis</z:hpo> or <z:hpo ids='HP_0011874'>heparin-induced thrombocytopenia</z:hpo>) were not observed </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Considering these results high-dose low-molecular-weight <z:chebi fb="5" ids="28304">heparin</z:chebi> and low dose aspirin prophylaxis is recommended for pregnant women with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> throughout pregnancy </plain></SENT>
</text></document>